Pluristem Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics

PSTI 8.720

+0.2%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: xcentral1	3/21/2012 9:25:44 AM
	2 Recommendations of 295

This is WONDERFUL!!!! In 2020, Pluristem Therapeutics; PLX-PAD Will Earn Decision Resources; Proprietary Clinical Gold Standard Status for the Treatment of Peripheral Arterial Disease PLX-PAD Will Displace the Current Proprietary Clinical Gold Standard for the Indication, Ramipril, According to Findings from Decision Resources BURLINGTON, Mass., Mar 21, 2012

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next